Registration Is Now Open for Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event on July 30, 2020
July 27 2020 - 9:30AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage
biopharmaceutical company with a current focus on breast cancer and
COVID-19, announces that Atossa’s CEO, Dr. Steven Quay, M.D.,
Ph.D., will present at Tribe Public’s Zoom Webinar Presentation and
Q&A Event that is scheduled to begin at 8am pacific/11am
eastern on Thursday, July 30th. During this complimentary,
30-minute event, Dr. Quay will present the company followed by a
Q&A session regarding Atossa’s breast cancer development
programs and recent progress with its two COVID-19 treatment
programs. To register to join the complimentary event, please visit
the Tribe Public LLC website: www.tribepublic.com, or send a
message to Tribe’s management at research@tribepublic.com to
request your seat for this limited capacity Zoom-based event.
Steven Quay, M.D., Ph.D. is the founder of
Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS). He received
his M.D. and Ph.D. from The University of Michigan, was a
postdoctoral fellow in the Chemistry Department at MIT with Nobel
Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital
and spent almost a decade on the faculty of Stanford University’s
School of Medicine. His contributions to medicine have been cited
9,890 times. He has founded six startups, invented seven
FDA-approved pharmaceuticals, and holds 87 US patents. Over 80
million people have benefited from the medicines he invented. His
current passions are solving big medical problems: stopping
the COVID-19 pandemic and preventing the two million breast cancers
in the world each year. Dr. Quay’s recently-published and highly
acclaimed book titled “COVID-19 Survival Manual: A Physician’s
Guide to Keep You and Your Family Healthy During the Pandemic and
Beyond” is available at his website: www.drquay.com.
ABOUT ATOSSA
THERAPEUTICS
Atossa Therapeutics, Inc. is a clinical-stage
biopharmaceutical company seeking to discover and develop
innovative medicines in areas of significant unmet medical need
with a current focus on breast cancer and COVID-19. For more
information, please visit www.atossatherapeutics.com.
ABOUT TRIBE PUBLIC LLC
Tribe Public LLC is a San Francisco, CA based
organization that hosts complimentary worldwide webinar &
meeting events in the U.S. Tribe’s complimentary events focus on
issues that the Tribe members care about with an emphasis on
hosting management teams from publicly traded companies from all
sectors & financial organizations that are seeking to increase
awareness of their products, progress and plans. Tribe members
primarily include Family Offices, Portfolio Managers, Registered
Investment Advisors, & Accredited Investors. Website:
http://www.tribepublic.com/.
FORWARD-LOOKING
STATEMENTS
Forward-looking statements in this press release,
which Atossa undertakes no obligation to update, are subject to
risks and uncertainties that may cause actual results to differ
materially from the anticipated or estimated future results,
including the risks and uncertainties associated with the
following: whether in vitro test results will also be
achieved in in vivo studies, including human clinical
studies, actions by and interactions with the FDA, the outcome or
timing of regulatory approvals needed by Atossa including those
needed to commence human clinical studies of AT-301 and the outcome
of such trials, lower than anticipated rate of patient enrollment,
the safety and efficacy of Atossa’s product candidates, performance
of developers and manufacturers, clinical research organizations
and investigators, obstacles resulting from proprietary rights held
by others such as patent rights, uncertainties affecting our
ability to secure patent protection for AT-301 or AT-H201 and other
risks detailed from time to time in Atossa’s filings with the
Securities and Exchange Commission, including without limitation
its periodic reports on Form 10-K and 10-Q, each as amended and
supplemented from time to time.
Company Contact: Atossa Therapeutics, Inc. Kyle
Guse, CFO and General Counsel Office: (866) 893-4927
kyle.guse@atossainc.com
Investor Relations Contact: Core IR Office: (516)
222-2560 ir@atossainc.com
Source: Atossa Therapeutics, Inc.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2024 to May 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From May 2023 to May 2024